Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35176150.
- Also identified by DOI 10.1158/1078-0432.CCR-21-4592.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The combination of chemotherapy and immune therapies still promises to synergize for prolonged tumor control. However, the quest for optimal combinations tailored for tumor histology remains ongoing. A recent study provides evidence on the feasibility of the trabectedin/durvalumab combination and reports on interesting preliminary efficacy. See related article by Toulmonde et al., p. 1765.
Medical subject headings
- Ovarian Neoplasms
- Sarcoma
- Soft Tissue Neoplasms
- Tetrahydroisoquinolines